Health Condition 1: null- Daâ?? al-Sadaf (Psoriasis)
Conditions
Interventions
Intervention1: Unani Drugs: Majoon Mundi (Oral), Qairooti-e-Karnab (Local): Majoon Mundi- Dosage Form: Majoon (semisolid).
Dose: 5 gm twice daily with 200 ml of water.
Route of Administration: Oral.
D
Sponsors
Central Research Institute of Unani Medicine
Eligibility
Inclusion criteria
Inclusion criteria: Participants of any sex in the age group between 18 and 65 years Participants with clinically diagnosed Da al-Sadaf (Psoriasis) of plaque type Psoriasis area severity index (PASI) of more or less than 10%
Exclusion criteria
Exclusion criteria: Pregnant and lactating women Participants with renal, hepatic or severe cardiac disease Participant unsure about attending treatment schedule regularly Participants who have received systemic therapy for psoriasis in last 2 months Participants who have received immunosuppressive/ immune-modulating treatment in last 2 months
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The response to treatment will be assessed using the following parameters: 1. Reduction in Psoriasis Area Severity Index (PASI) 2. Improvement in Investigators Global Assessment (IGA)Timepoint: at baseline, 2, 4, 6, 8, 10 and 12 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| Improvement in the quality of lifeTimepoint: at baseline, 2, 4, 6, 8, 10 and 12 weeks | — |
Countries
India
Contacts
Public ContactProf Qamar Uddin
Central Research Institute of Unani Medicine, Hyderabad
Outcome results
None listed